0.759  0.069 (10%)		07-26 16:00
Open: 0.7388 High: 0.77 Volume: 92,287		Pre. Close: 0.69 Low: 0.7001 Market Cap: 63(M)

Short term
Mid term
Targets	6-month :	0.89	1-year :	1.05
Resists	First :	0.76	Second :	0.89
Pivot price	0.67
Supports	First :	0.66	Second :	0.6
MAs	MA(5) :	0.72	MA(20) :	0.66
	MA(100) :	0.74	MA(250) :	0.86
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	82.8	D(3) :	83.3
RSI	RSI(14): 61.2
52-week	High :	1.39	Low :	0.55

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VNRX ] has closed below upper band by 3.7%. Bollinger Bands are 17.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.77 - 0.77	0.77 - 0.78
Low:	0.69 - 0.7	0.7 - 0.7
Close:	0.75 - 0.76	0.76 - 0.76

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Tue, 23 Jul 2024
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - MarketBeat

Tue, 23 Jul 2024
VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com - Defense World

Tue, 16 Jul 2024
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World

Tue, 16 Jul 2024
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - American Banking and Market News

Mon, 15 Jul 2024
StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX) - MarketBeat

Wed, 03 Jul 2024
VolitionRx expands stock plan and authorized shares By Investing.com - Investing.com UK

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	0 (M)
Shares Float	79 (M)
Held by Insiders	5.949e+007 (%)
Held by Institutions	24.6 (%)
Shares Short	794 (K)
Shares Short P.Month	0 (K)

EPS	-3.415e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-5 %
Return on Assets (ttm)	237.5 %
Return on Equity (ttm)	-106.5 %
Qtrly Rev. Growth	651040 %
Gross Profit (p.s.)	251.55
Sales Per Share	0
EBITDA (p.s.)	190304
Qtrly Earnings Growth	-0.6 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-30 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-40.74

Dividend	0
Forward Dividend	704050
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.